New Lung Cancer Approaches Suggested in Mutation Study
ST. LOUIS, Oct. 22 — Some drugs not previously considered to have potential in lung cancer treatment may, in fact, be helpful in the condition, researchers here said.
Detailed genomic analysis of 188 lung adenocarcinoma specimens revealed mutations in pathways associated with such drugs as rapamycin (Rapamune), sunitinib (Sutent), and sorafenib (Nexavar), reported Li Ding, Ph.D., of Washington University, and colleagues in the Oct. 23 issue of Nature.